Compare STTK & ITRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | ITRG |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 572.1M |
| IPO Year | 2020 | 2017 |
| Metric | STTK | ITRG |
|---|---|---|
| Price | $4.18 | $2.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $10.00 | $5.13 |
| AVG Volume (30 Days) | 860.8K | ★ 2.8M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $67.34 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | $45.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.43 |
| 52 Week High | $8.33 | $4.87 |
| Indicator | STTK | ITRG |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 42.26 |
| Support Level | $3.67 | N/A |
| Resistance Level | $4.23 | $3.29 |
| Average True Range (ATR) | 0.51 | 0.14 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 27.29 | 29.63 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.